Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | TYMS | P04818 | 2/20 | 0.57 |
| ▸ | TK1 | P04183 | 2/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | TK2 | O00142 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277164 | 1.00 | LMNA (0.70) | LMNASMN1; SMN2TYMSTK1ALOX12 | |
| SCHEMBL20854761 | 0.89 | LMNA (0.67) | LMNASMN1; SMN2TYMSTK1ALOX12 | |
| SCHEMBL9856524 | 0.89 | LMNA (0.57) | LMNASMN1; SMN2TYMSTK1 | |
| SCHEMBL263767 | 0.88 | POLB (0.64) | TYMSTK1 | |
| SCHEMBL263768 | 0.88 | POLB (0.64) | TYMSTK1 | |
| SCHEMBL15216188 | 0.88 | POLB (0.64) | TYMSTK1 | |
| SCHEMBL18744110 | 0.88 | LMNA (0.74) | LMNASMN1; SMN2TYMSTK1ALOX12 | |
| SCHEMBL15788461 | 0.88 | LMNA (0.74) | LMNASMN1; SMN2TYMSTK1ALOX12 | |
| SCHEMBL10708167 | 0.88 | LMNA (0.74) | LMNASMN1; SMN2TYMSTK1ALOX12 | |
| SCHEMBL10708169 | 0.88 | LMNA (0.74) | LMNASMN1; SMN2TYMSTK1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56115798-A | — | — | None | — | — | JP | disclosed |
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2009-04-23 | — | — | US | disclosed |
| US-4868162-A | 5-HALO-2*-DEOXYURIDINE DERIVATIVE | TEIJIN LIMITED (JP) | 1989-09-19 | — | — | US | disclosed |
| JP-S56115798-A | 2'-DEOXY-3',5'-DI-O-ACETYL-5-FLUOROURIDINE DERIVATIVE, ITS PREPARATION, AND ANTITUMOR AGENT CONTAINING THE SAME | FUNAI CORP | 1981-09-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | TYMP, ENTPD5, NUDT1 | LMNA 256/4885SMN1; SMN2 2604/4885TYMS 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.